The company closed its plan on May 14, 2024.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
38.46 CNY | -1.99% |
|
-3.95% | -14.97% |
18/06 | Hengrui Pharmaceuticals, Subsidiary Get Regulatory Nod to Test Two Drugs | MT |
05/06 | Hengrui Pharma Units Get China Nod for Clinical Trial of Tumor Drug | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.97% | 3.37TCr | |
+55.32% | 82TCr | |
+44.05% | 64TCr | |
-6.75% | 35TCr | |
+13.56% | 31TCr | |
+10.68% | 30TCr | |
+16.57% | 24TCr | |
+13.31% | 22TCr | |
+8.48% | 17TCr | |
-2.81% | 16TCr |
- Stock Market
- Equities
- 600276 Stock
- News Jiangsu Hengrui Medicine Co., Ltd.
- Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback announced on May 15, 2023, has closed with 14,351,878 shares, representing 0.22% for CNY 634.67 million.